| Literature DB >> 9090386 |
K Virtaneva1, E D'Amato, J Miao, M Koskiniemi, R Norio, G Avanzini, S Franceschetti, R Michelucci, C A Tassinari, S Omer, L A Pennacchio, R M Myers, J L Dieguez-Lucena, R Krahe, A de la Chapelle, A E Lehesjoki.
Abstract
Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1; MIM 254800) is an autosomal recessive disorder that occurs with a low frequency in many populations but is more common in Finland and the Mediterranean region. It is characterized by stimulus-sensitive myoclonus and tonic-clonic seizures with onset at age 6-15 years, typical electroencephalographic abnormalities and a variable rate of progression between and within families. Following the initial mapping of the EPM1 gene to chromosome 21 (ref. 6) and the refinement of the critical region to a small interval, positional cloning identified the gene encoding cystatin B (CST6), a cysteine protease inhibitor, as the gene underlying EPM1 (ref. 10). Levels of messenger RNA encoded by CST6 were dramatically decreased in patients. A 3' splice site and a stop codon mutation were identified in three families, leaving most mutations uncharacterized. In this study, we report a novel type of disease-causing mutation, an unstable 15- to 18-mer minisatellite repeat expansion in the putative promoter region of the CST6 gene. The mutation accounts for the majority of EPM1 patients worldwide. Haplotype data are compatible with a single ancestral founder mutation. The length of the repeat array differs between chromosomes and families, but changes in repeat number seem to be comparatively rare events.Entities:
Mesh:
Substances:
Year: 1997 PMID: 9090386 DOI: 10.1038/ng0497-393
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330